Zostavax Gets Nod For Younger Age Group, But Supply Issues Make Sales Boost Unlikely
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck's ability to capitalize on FDA approval of the shingles vaccine in patients ages 50-59 years is questionable given ongoing supply constraints.
You may also be interested in...
Merck Faces Varicella-Zoster Virus Supply Shortage For Vaccine Production
Merck does not expect problems in the production of bulk varicella-zoster virus vaccine to affect near-term supplies of individual products that contain the virus - the varicella vaccine Varivax, the herpes zoster vaccine Zostavax, and the measles, mumps, rubella and varicella (MMR-V) combination ProQuad
Merck’s Zostavax Shingles Vaccine Approved For Patients Over 60
FDA says Merck would need to present more data to pursue use in patients ages 50-59.
Merck Zostavax Shingles Vaccine Safe and Effective For Adults Over 60, Committee Says
FDA's Vaccines & Related Biological Products Advisory Committee said data do not support Merck's proposed indication for adults as young as 50 years.